{
  "docId": "019f6b8e-d87d-74a8-98e5-6fc840cf4742",
  "docSlug": "jarvis-10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup",
  "documentTitle": "10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup",
  "authorId": "10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup",
  "authorName": null,
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2012-01-01 00:00:00",
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 12,
  "pageCount": 27,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "Includes two bar charts showing historical/projected growth and a median benchmark line.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019f6b8e-d87d-74a8-98e5-6fc840cf4742/12",
  "deckHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742",
  "deckJsonHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742.json",
  "deckAnchorHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.28,
        "w": 0.85,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "chart",
      "text": "2012E - 2013E Revenue Growth",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71ca0664-916a-4ff5-bcb6-aca19d646e8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.85,
        "x": 0.07,
        "y": 0.21
      },
      "kind": "chart",
      "text": "2011A - 2012E Revenue Growth",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d89c8659-5a8e-4cc5-b4db-00d71b530565",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.07,
        "y": 0.87
      },
      "kind": "other",
      "text": "(1) Median excludes Taro. (2) Not pro forma for Actavis acquisition. (3) Perrigo 2011A revenue adjusted for full year of Paddock revenue based on 12/31/2011 10Q. (4) Par revenue adjusted to exclude revenue associated with acquisition of marketing rights to generic Provigil. (5) Impax revenue adjusted to exclude revenue associated with acquisition of Zomig.",
      "attrs": null,
      "subkind": "annotation",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66812184-5847-41a3-a51e-35edce1d4207",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.07,
        "y": 0.85
      },
      "kind": "other",
      "text": "Sources: Taro financial projections as per management's 5-year forecast, FactSet, Wall Street Research.",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bbd21d2-035f-4d0c-bb7f-31aacc834ce3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Taro is expected to grow more quickly than most of its US generic peers in 2012, however, as competitors re-enter select Taro product markets, pricing and volume are projected to be pressured, leading to declining growth.",
      "attrs": null,
      "subkind": "description",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a8db7b0-fba9-4e63-aad0-6144a02525bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "Generic Pharma Peer Benchmarking",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fdbba1d-98ca-4969-a613-137b3fd75a26",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "748cfcb7-24a0-46bf-965c-541006f58999",
      "evidence": "Peer benchmarking of revenue growth rates",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "3645375d-f4dc-48bf-b0fa-4457c0ee9f91",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "The document presents detailed financial data and peer benchmarking",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 12,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "f7b706e2-cbe9-4c86-a2b1-72d90dd7a7df",
      "evidence": "The document presents multiple peer benchmarking analyses",
      "position": 0,
      "objective": "Identify patterns in peer benchmarking",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}